c52d39b7-3811-41e5-bdc8-9ed59632a903
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.400
- CHOLESTEROL_HOMEOSTASIS+0.400
- ESTROGEN_RESPONSE_EARLY+0.400
- ESTROGEN_RESPONSE_LATE+0.400
- KRAS_SIGNALING_DN+0.400
- APICAL_SURFACE+0.300
- COAGULATION+0.300
- FATTY_ACID_METABOLISM+0.300
- ADIPOGENESIS+0.200
- ANDROGEN_RESPONSE+0.200
Top 10 suppressed
- DNA_REPAIR-0.600
- MYC_TARGETS_V1-0.600
- MYC_TARGETS_V2-0.600
- E2F_TARGETS-0.500
- G2M_CHECKPOINT-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.400
- INTERFERON_GAMMA_RESPONSE-0.300
- MITOTIC_SPINDLE-0.300
- OXIDATIVE_PHOSPHORYLATION-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2208930 | — | — | 0.915 |
| 2 | BS_GYA4V1RD | pilocytic astrocytoma | — | 0.857 |
| 3 | s0112281 | — | — | 0.836 |
| 4 | BS_GV3NZ9QD | EPN | EPN Tumor | 0.827 |
| 5 | 7645a3b1-639d-4677-8bcf-c16df24fcc2b | — | — | 0.827 |
| 6 | s0122230 | — | — | 0.825 |
| 7 | SRR1409305 | GTEX | — | 0.821 |
| 8 | BS_1G3WYEN3 | low-grade glioma | — | 0.821 |
| 9 | SRR1313091 | — | A | 0.818 |
| 10 | s0112300 | — | — | 0.808 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.400 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.400 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.400 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.400 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |